Abstract Background Neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy represents the current standard of care for HER2-positive breast cancer. However, marked heterogeneity in patient response has intensified discussions on treatment de-escalation for low-risk individuals and alternative therapies for resistant cases. Presently, clinically robust precision oncology tools facilitating such individualized therapeutic strategies remain unavailable. Methods We developed HER2-LADDER (Layered AI-based Dual-targeteD anti-HER2 Recommendation), an AI-driven decision-support framework that integrates clinicopathological information with spatial features derived from routine hematoxylin and eosin (H 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-06-09.
Wu et al. (Tue,) studied this question.